Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial
This work was supported by Niagen Bioscience, the MGH McCance Center for Brain Health, Lavine Brain Health Innovation Fund, MGH ECOR CDI Physician-Scientist Development Award, and the Alzheimer's Association (grant no. AARGD-23-114103).
Authors
- Jonathan Rosand (ORCID: https://orcid.org/0000-0002-1014-9138)
- Alison J. McManus
- Chao‐Yi Wu (ORCID: https://orcid.org/0000-0002-2187-6509)
- William Reynolds (ORCID: https://orcid.org/0000-0002-7240-5213)
- Edmarie Guzmán‐Vélez (ORCID: https://orcid.org/0000-0002-3076-0727)
- Rudolph E. Tanzi (ORCID: https://orcid.org/0000-0002-7032-1454)
- Olivia Sun (ORCID: https://orcid.org/0009-0009-4011-0750)
- Charles Brenner (ORCID: https://orcid.org/0000-0002-4955-3226)
- Steven Edward Arnold (ORCID: https://orcid.org/0000-0002-9487-415X)
- Leidys Gutiérrez-Martínez (ORCID: https://orcid.org/0000-0003-0593-493X)
- Isabel Abril
- Gabriel González-Irizarry
Institutions
- Broad Institute (US)
- Allen Institute for Brain Science (US)
- Harvard University (US)
- Henry Ford College (US)
- Massachusetts General Hospital (US)
- City of Hope (US)
- Institute for Neurodegenerative Disorders (US)
- Institute on Aging (US)
- Center for Pain and the Brain (US)
- Center for Genomic Science (IT)
- Harvard Global Health Institute (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103633
- Citations
- 1
- Primary Topic
- Calcium signaling and nucleotide metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.12